Latest Progenics Pharmaceuticals Inc (PGNX) Headlines
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2013 Financial Results and Initiates Clinical Development of Small Molecule Targeted Therapeutic
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) today announced its results of operations for the fourth quarter and year-end 2013. The company also announced that it is initiating clinical development of MIP-1095, a PSMA-targeted small molecule radiopharmaceutical for the treatment of prostate cancer.
Stock to Watch: Progenics Pharmaceuticals Up 5.9% (PGNX)
Comtex SmarTrend(R) - Tue Mar 11, 10:41AM CDT
Progenics Pharmaceuticals (NASDAQGNX) is one of today's best performing low-priced stocks, up 5.9% to $4.88 on 1.4x average daily volume. Progenics Pharmaceuticals has traded 2.3 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's 0.1%) and outperformed the S&P 500 (5.9% to the S&P's 0.1%) during today's trading.
Progenics Pharmaceuticals Sets 4Q and Year-End 2013 Financial Results Call for March 13
GlobeNewswire - Mon Mar 10, 12:48PM CDT
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review fourth quarter and full-year 2013 financial results on Thursday, March 13, at 8:30 a.m. ET.
Progenics Pharmaceuticals Sets 1Q 2014 Financial Results Call for March 13
GlobeNewswire - Tue Mar 04, 11:00AM CST
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review first quarter financial results on Thursday, March 13, at 8:30 a.m. ET.
Progenics to Raise Funds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 11:10AM CST
Progenics to raise funds for research and development (R&D) activities and general corporate purposes
Progenics Pharmaceuticals prices public offering at USD4.60 per share
M2 - Mon Feb 24, 6:12AM CST
US-based medical company Progenics Pharmaceuticals (NasdaqGSGNX) said on Friday that it has priced its public offering of 7,608,696 primary shares of its common stock at USD4.60 per share.
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Feb 21, 8:00AM CST
Progenics Pharmaceuticals, Inc. (NasdaqGNX) announced today the pricing of an underwritten public offering of 7,608,696 primary shares of its common stock at a public offering price of $4.60 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $35 million. The offering is expected to close on or about February 26, 2014, subject to customary closing conditions. Progenics also granted the underwriters a 30-day option to purchase 1,141,304 additional shares of common stock. All of the shares to be sold in the offering are to be sold by Progenics. Progenics intends to use the net proceeds from the offering for research and development and general corporate purposes.
Progenics Pharmaceuticals to launch public offering of common shares
M2 - Fri Feb 21, 4:31AM CST
US-based oncology medicine specialists Progenics Pharmaceuticals (NasdaqGSGNX) said on Thursday that it plans to sell shares of its common stock in an underwritten public offering.
Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Feb 20, 3:01PM CST
Progenics Pharmaceuticals, Inc. (NasdaqGNX) announced today that it is offering to sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Jefferies LLC is acting as sole book-running manager for the proposed offering. Progenics also intends to grant the underwriter a 30-day option to purchase additional shares of common stock on the same terms and conditions. All of the shares to be sold in the offering are to be sold by Progenics. Progenics intends to use the net proceeds from the offering for research and development and general corporate purposes.
Salix's sNDA on Relistor Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 4:40PM CST
Salix Pharmaceuticals announced disappointing news when the U.S. Food and Drug Administration (FDA) postponed the previously scheduled meeting on Mar 10-11 to consider the Supplemental New Drug Application (sNDA) for Relistor.
Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 1:30PM CST
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Mark R. Baker, CEO of Progenics, will present at the 16 Annual BIO CEO & Investor Conference which will be held February 10 and 11 at the Waldorf Astoria Hotel in New York City. The presentation will take place on Monday, February 10 at 3:00 PM EST.
Biotech Stock Roundup: Strong Show from Biogen & Alexion; Medivation PREVAILs - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 05, 7:29AM CST
Medivation stood out last week with its impressive data on prostate cancer therapy, Xtandi.
Why Progenics Pharmaceuticals, Inc. Jumped This Morning
Brian Pacampara, The Motley Fool - Motley Fool - Mon Feb 03, 3:36PM CST
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense. What: ...
Progenics Pharmaceuticals (PGNX) Is Today's Dead Cat Bounce Stock
at The Street - Mon Feb 03, 8:46AM CST
Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Upgrade Alert for Progenics Pharmaceuticals (PGNX)
Comtex SmarTrend(R) - Mon Feb 03, 7:09AM CST
Progenics Pharmaceuticals (NASDAQGNX) was upgraded from Hold to Buy at Needham today. The stock closed yesterday at $4.78 on volume of 2.2 million shares, above average daily volume of 1.6 million. Progenics Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics' principal programs are directed toward supportive care, virology (human immunodeficiency virus and hepatitis C virus infections), and oncology.
This Week in Biotech: Let's Get Clinical!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 01, 12:08PM CST
With the SPDR S&P Biotech Index up 58% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Progenics (PGNX) Worth Watching: Stock Jumps 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 8:25AM CST
Progenics was a big mover last session, with shares rising nearly 16%.
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 30, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Progenics Shares Fall as Safety Issues Crop Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 3:00PM CST
Progenics Pharmaceuticals shares nosedived after safety issues related to its prostate-specific membrane antigen antibody drug conjugate were revealed.
Progenics Pharmaceuticals Presents Positive Data From a Phase 2 Trial of PSMA ADC in Patients With Chemotherapy Experienced Metastatic Castrate Resistant Prostate Cancer
GlobeNewswire - Thu Jan 30, 1:30PM CST
Progenics Pharmaceuticals, Inc., (NasdaqGNX), an oncology company focused on developing innovative approaches to targeting and treating prostate cancer, today presented a poster entitled A Phase 2 trial of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) at the American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium in San Francisco, CA. The Phase 2 trial assessed the anti-tumor activity and tolerability of its antibody drug conjugate, PSMA ADC, in patients with metastatic castrate resistant prostate cancer. A total of 83 patients who had progressive disease despite treatment with at least one taxane containing chemotherapy received PSMA ADC. Enrollment of a chemotherapy naïve cohort is ongoing.
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2013 Financial Results and Initiates Clinical Development of Small Molecule Targeted Therapeutic
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) today announced its results of operations for the fourth quarter and year-end 2013. The company also announced that it is initiating clinical development of MIP-1095, a PSMA-targeted small molecule radiopharmaceutical for the treatment of prostate cancer. Stock to Watch: Progenics Pharmaceuticals Up 5.9% (PGNX)
Comtex SmarTrend(R) - Tue Mar 11, 10:41AM CDT
Progenics Pharmaceuticals (NASDAQ
GNX) is one of today's best performing low-priced stocks, up 5.9% to $4.88 on 1.4x average daily volume. Progenics Pharmaceuticals has traded 2.3 million shares thus far today, vs. average volume of 1.6 million shares per day. The stock has outperformed the Dow (5.9% to the Dow's 0.1%) and outperformed the S&P 500 (5.9% to the S&P's 0.1%) during today's trading. Progenics Pharmaceuticals Sets 4Q and Year-End 2013 Financial Results Call for March 13
GlobeNewswire - Mon Mar 10, 12:48PM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review fourth quarter and full-year 2013 financial results on Thursday, March 13, at 8:30 a.m. ET. Progenics Pharmaceuticals Sets 1Q 2014 Financial Results Call for March 13
GlobeNewswire - Tue Mar 04, 11:00AM CST
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review first quarter financial results on Thursday, March 13, at 8:30 a.m. ET. Progenics to Raise Funds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 11:10AM CST
Progenics to raise funds for research and development (R&D) activities and general corporate purposes
Progenics Pharmaceuticals prices public offering at USD4.60 per share
M2 - Mon Feb 24, 6:12AM CST
US-based medical company Progenics Pharmaceuticals (NasdaqGS
GNX) said on Friday that it has priced its public offering of 7,608,696 primary shares of its common stock at USD4.60 per share. Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Feb 21, 8:00AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) announced today the pricing of an underwritten public offering of 7,608,696 primary shares of its common stock at a public offering price of $4.60 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $35 million. The offering is expected to close on or about February 26, 2014, subject to customary closing conditions. Progenics also granted the underwriters a 30-day option to purchase 1,141,304 additional shares of common stock. All of the shares to be sold in the offering are to be sold by Progenics. Progenics intends to use the net proceeds from the offering for research and development and general corporate purposes. Progenics Pharmaceuticals to launch public offering of common shares
M2 - Fri Feb 21, 4:31AM CST
US-based oncology medicine specialists Progenics Pharmaceuticals (NasdaqGS
GNX) said on Thursday that it plans to sell shares of its common stock in an underwritten public offering. Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Feb 20, 3:01PM CST
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) announced today that it is offering to sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Jefferies LLC is acting as sole book-running manager for the proposed offering. Progenics also intends to grant the underwriter a 30-day option to purchase additional shares of common stock on the same terms and conditions. All of the shares to be sold in the offering are to be sold by Progenics. Progenics intends to use the net proceeds from the offering for research and development and general corporate purposes. Salix's sNDA on Relistor Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 4:40PM CST
Salix Pharmaceuticals announced disappointing news when the U.S. Food and Drug Administration (FDA) postponed the previously scheduled meeting on Mar 10-11 to consider the Supplemental New Drug Application (sNDA) for Relistor.
Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 06, 1:30PM CST
Progenics Pharmaceuticals, Inc. (PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Mark R. Baker, CEO of Progenics, will present at the 16 Annual BIO CEO & Investor Conference which will be held February 10 and 11 at the Waldorf Astoria Hotel in New York City. The presentation will take place on Monday, February 10 at 3:00 PM EST.
Biotech Stock Roundup: Strong Show from Biogen & Alexion; Medivation PREVAILs - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 05, 7:29AM CST
Medivation stood out last week with its impressive data on prostate cancer therapy, Xtandi.
Why Progenics Pharmaceuticals, Inc. Jumped This Morning
Brian Pacampara, The Motley Fool - Motley Fool - Mon Feb 03, 3:36PM CST
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense. What: ...
Progenics Pharmaceuticals (PGNX) Is Today's Dead Cat Bounce Stock
at The Street - Mon Feb 03, 8:46AM CST
Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Upgrade Alert for Progenics Pharmaceuticals (PGNX)
Comtex SmarTrend(R) - Mon Feb 03, 7:09AM CST
Progenics Pharmaceuticals (NASDAQ
GNX) was upgraded from Hold to Buy at Needham today. The stock closed yesterday at $4.78 on volume of 2.2 million shares, above average daily volume of 1.6 million. Progenics Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics' principal programs are directed toward supportive care, virology (human immunodeficiency virus and hepatitis C virus infections), and oncology. This Week in Biotech: Let's Get Clinical!
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 01, 12:08PM CST
With the SPDR S&P Biotech Index up 58% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Progenics (PGNX) Worth Watching: Stock Jumps 15.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 8:25AM CST
Progenics was a big mover last session, with shares rising nearly 16%.
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 30, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Progenics Shares Fall as Safety Issues Crop Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 3:00PM CST
Progenics Pharmaceuticals shares nosedived after safety issues related to its prostate-specific membrane antigen antibody drug conjugate were revealed.
Progenics Pharmaceuticals Presents Positive Data From a Phase 2 Trial of PSMA ADC in Patients With Chemotherapy Experienced Metastatic Castrate Resistant Prostate Cancer
GlobeNewswire - Thu Jan 30, 1:30PM CST
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative approaches to targeting and treating prostate cancer, today presented a poster entitled A Phase 2 trial of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) at the American Society of Clinical Oncology's 2014 Genitourinary Cancers Symposium in San Francisco, CA. The Phase 2 trial assessed the anti-tumor activity and tolerability of its antibody drug conjugate, PSMA ADC, in patients with metastatic castrate resistant prostate cancer. A total of 83 patients who had progressive disease despite treatment with at least one taxane containing chemotherapy received PSMA ADC. Enrollment of a chemotherapy naïve cohort is ongoing. 
